Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Associated Therapies: -

Clinical Trials

Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction

Phase 4

Conditions: ST Elevation Myocardial Infarction

Interventions: Drug: Ticagrelor
Drug: Clopidogrel

First Posted Date: 2014-08-25

Last Posted Date: 2016-11-15

Lead Sponsor: Gyeongsang National University Hospital

Target Recruit Count: 326

Registration Number: NCT02224534

Locations: 🇰🇷
Chonnam National University Hospital, Gwangju, CHONRANAM-Do, Korea, Republic of
🇸🇬
National University Heart Centre, Singapore, Singapore
🇰🇷
Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of

and more 9 locations

Antiplatelet Therapy After Cardiac Arrest

Phase 4

Completed

Conditions: Postresuscitation Syndrome
Cardiac Arrest
Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)

Interventions: Drug: Clopidogrel
Drug: Ticagrelor

First Posted Date: 2014-08-25

Last Posted Date: 2019-02-27

Lead Sponsor: University Medical Centre Ljubljana

Target Recruit Count: 57

Registration Number: NCT02224274

Locations: 🇸🇮
University Medical Centre Ljubljana, Ljubljana, Slovenia

Influence of Clopidogrel on the Pharmacodynamics and Safety of Terbogrel in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Terbogrel
Drug: Clopidogrel

First Posted Date: 2014-08-22

Last Posted Date: 2014-08-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT02222987

Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

Phase 3

Completed

Conditions: Peripheral Arterial Disease

Interventions: Drug: Clopidogrel
Drug: Acetylsalicylic acid (ASA)

First Posted Date: 2014-08-15

Last Posted Date: 2021-02-21

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 159

Registration Number: NCT02217501

Locations: 🇺🇸
VA North Texas Health Care System, Dallas, Texas, United States
🇺🇸
Midwest Cardiovascular Research Foundation, Davenport, Iowa, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

and more 1 locations